Nektar(NKTR) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - The company ended 2025 with $245.8 million in cash and investments and no debt on its balance sheet [9][23] - Revenue for Q4 2025 was $21.8 million, and for the full year, it was $55.2 million [24] - R&D expenses for Q4 2025 were $29.7 million, totaling $117.3 million for the year [24] - G&A expenses for Q4 2025 were $11.2 million, with a full-year total of $68.7 million [24] - The net loss for Q4 2025 was $36.1 million, or $1.78 per share, while the full-year net loss was $164.1 million, or $9.73 per share [24][25] Business Line Data and Key Metrics Changes - The company focused on advancing its immunology and inflammation pipeline, particularly the Treg biologic, rezpegaldesleukin [3][4] - Positive results were achieved in phase 2b studies for atopic dermatitis and alopecia areata, validating the efficacy of the Treg mechanism [4][5] - The atopic dermatitis market is projected to grow to approximately $35 billion by the mid-2030s, with only 10%-15% of patients currently receiving biologic treatments [5][6] Market Data and Key Metrics Changes - In the U.S., over 15 million people suffer from moderate to severe atopic dermatitis, presenting a significant market opportunity [5] - The competitive landscape for late-stage novel mechanisms of action (MOAs) has narrowed, positioning REZPEG favorably [6][7] Company Strategy and Development Direction - The company plans to initiate phase 3 studies for rezpegaldesleukin in June 2026, with a BLA submission targeted for 2029 [9][10] - The strategy includes leveraging a differentiated efficacy and safety profile for REZPEG, aiming to provide a better dosing regimen compared to existing treatments [6][7] - The company is also exploring additional indications for REZPEG, including type 1 diabetes and other autoimmune diseases [20][21] Management's Comments on Operating Environment and Future Outlook - Management highlighted the importance of the Treg mechanism in addressing various diseases and expressed optimism about the potential for REZPEG to achieve significant market penetration [20][21] - The company anticipates that the phase 3 program will provide robust data supporting the efficacy and safety of REZPEG, which could lead to a strong competitive position in the market [9][10] Other Important Information - The company raised approximately $476 million in additional net cash through a public offering and ATM exercises since year-end 2025 [9][23] - The phase 3 program for atopic dermatitis will include both biologic-naive and treatment-experienced patients, with a focus on achieving significant clinical endpoints [10][11] Q&A Session Summary Question: What type of new data can be expected from the AAD conference? - The upcoming presentation will showcase additional effects of treatment with REZPEG and the potential for more patients to achieve SALT 20 responses [29][30] Question: Will ACQ-5 data be included in the phase 3 program? - Yes, ACQ-5 will be included, and efforts will be made to incorporate it into the label [36][37] Question: What is the formulation or device for REZPEG being considered? - The plan is to launch REZPEG in an auto-injector device, with weight-banded dosing for ease of administration [41][47] Question: How does REZPEG differentiate from other treatments in type 1 diabetes? - REZPEG offers an outpatient dosing regimen without the need for routine monitoring, contrasting with the more complex administration of other treatments [78][79]